Wall Street analyst estimates for Niagen Bioscience Inc (NAGE): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredi...
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-03 | $0.01 | ||
| 2026-08-04 | $0.01 | $0.01 | +20.0% |
| 2026-05-06 | $0.07 | $0.06 | +16.7% |
| 2026-03-04 | $0.03 | $0.02 | +50.0% |
| 2025-11-04 | $0.05 | $0.01 | +233.3% |
| 2025-08-06 | $0.04 | $0.02 | +100.0% |
| 2025-05-07 | $0.04 | $0.02 | +100.0% |
| 2025-03-04 | $0.09 | $0.02 | +300.0% |
Valuation Ratios
| P/E Ratio | 15.45 |
| Price / Book | 2.88 |
| EV / EBITDA | 9.62 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.7M | $21.2M | $31.6M | $46.3M | $59.3M | $67.4M | $72.0M | $83.6M | $99.6M | $129.4M |
| Cost of Revenue | $11.3M | $10.7M | $15.5M | $20.5M | $24.0M | $26.0M | $29.3M | $32.8M | $38.0M | $46.2M |
| Gross Profit | $10.4M | $10.5M | $16.1M | $25.8M | $35.3M | $41.5M | $42.8M | $50.8M | $61.6M | $83.2M |
| Research & Development | $2.5M | $4.0M | $5.5M | $4.4M | $3.4M | $3.8M | $4.8M | $5.0M | $6.0M | $6.3M |
| Selling, General & Admin | $10.8M | $22.1M | $43.7M | $52.5M | $51.7M | $64.7M | $56.6M | $51.4M | $47.8M | $62.6M |
| Operating Expenses | $13.3M | $26.9M | $49.2M | $57.1M | $55.1M | $68.6M | $61.4M | $56.4M | $53.9M | $68.9M |
| Operating Income | -$2.9M | -$16.4M | -$33.2M | -$31.3M | -$19.9M | -$27.1M | -$18.6M | -$5.6M | $7.7M | $14.3M |
| EBITDA | -$2.5M | -$15.7M | -$32.3M | -$29.8M | -$18.3M | -$25.4M | -$14.7M | -$3.2M | $10.3M | $19.6M |
| Interest Expense | $371899 | $153000 | $79000 | $847000 | $71000 | $55000 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$3.6M | -$16.5M | -$33.3M | -$32.1M | -$19.9M | -$27.1M | -$16.5M | -$4.9M | $8.9M | $18.2M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $305000 | $810000 |
| Net Income | -$2.9M | -$11.4M | -$33.3M | -$32.1M | -$19.9M | -$27.1M | -$16.5M | -$4.9M | $8.6M | $17.4M |
| EPS | $-0.08 | $-0.26 | $-0.61 | $-0.56 | $-0.33 | $-0.40 | $-0.24 | $-0.07 | $0.11 | $0.22 |
| EPS (Diluted) | $-0.08 | $-0.26 | $-0.61 | $-0.56 | $-0.33 | $-0.40 | $-0.24 | $-0.07 | $0.11 | $0.20 |
| Shares Outstanding (Diluted) | $37.3M | $44.6M | $55.0M | $57.1M | $61.1M | $67.2M | $69.7M | $75.0M | $79.7M | $85.4M |
Price
| Price | $3.00 |
| Market Cap | $239M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AKBA · CRVS · KALV · KROS · OLMA · PRTA · RGNX
Explore sector: Healthcare · Biotechnology
More sections of NAGE: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks